BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 9764815)

  • 21. [Experience with use of mustoforan at the Clinical Oncological Dispensary of the Republic of Tatarstan].
    Karpenko LG
    Vopr Onkol; 2005; 51(3):388-90. PubMed ID: 16279110
    [No Abstract]   [Full Text] [Related]  

  • 22. [Therapeutic strategies and systemic treatment of brain melanoma metastases].
    Durando X; Mansard S; Daste A; Gimbergues P; Brocard L; Magné N; Thivat E
    Bull Cancer; 2013 Jan; 100(1):23-8. PubMed ID: 22889847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete remission seven years after treatment for metastatic malignant melanoma.
    Petit T; Borel C; Rixe O; Avril MF; Monnier A; Giroux B; Weil M; Khayat D
    Cancer; 1996 Mar; 77(5):900-2. PubMed ID: 8608481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impressive objective response in a patient with extensive metastatic melanoma including the brain.
    Del Vecchio M; Canova S; Messina A; Bajetta E
    Melanoma Res; 2007 Oct; 17(5):332-4. PubMed ID: 17885590
    [No Abstract]   [Full Text] [Related]  

  • 25. Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.
    Terheyden P; Becker JC; Kämpgen E; Bröcker EB
    Melanoma Res; 2000 Oct; 10(5):475-82. PubMed ID: 11095409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fotemustine for the treatment of melanoma.
    Quéreux G; Dréno B
    Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [DNCB immunotherapy for removal of melanoma skin metastases].
    Wätzig V
    Dermatol Monatsschr; 1977 Oct; 163(10):848-50. PubMed ID: 923876
    [No Abstract]   [Full Text] [Related]  

  • 28. [Fotemustine: muphoran].
    Avril MF
    Ann Dermatol Venereol; 2007 Dec; 134(12):997-1000. PubMed ID: 18166925
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effectiveness and safety of combined mustoforan, cisplatin and tamoxifen for disseminated cutaneous melanoma (results of the IC4-10036-46-RU trial)].
    Konstantinova MM; Gershanovich ML; Akimov MA; Nosov DA; Bogdanova NV
    Vopr Onkol; 2005; 51(5):550-7. PubMed ID: 16756009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapy of malignant melanoma at the stage of distant metastasis].
    Garbe C; Eigentler TK
    Hautarzt; 2004 Feb; 55(2):195-213. PubMed ID: 15043023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Contribution of a new nitrosourea compound: fotemustine].
    Boaziz C
    Pathol Biol (Paris); 1992 Dec; 40(9 Pt 2):964-8. PubMed ID: 1338920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug.
    Addeo R; De Santi MS; Del Prete S; Caraglia M
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):863-6. PubMed ID: 19639315
    [No Abstract]   [Full Text] [Related]  

  • 33. Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
    Lopez V; Pinazo I; Marti N; Monteagudo C; Jorda E
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):959-60. PubMed ID: 18785888
    [No Abstract]   [Full Text] [Related]  

  • 34. [Immunochemotherapy of malignant melanoma. Epifocal administration of dinitrochlorobenzene (DNCB) combined with systemic chemotherapy with dacarbazine (DTIC)].
    Trcka J; Kämpgen E; Becker JC; Schwaaf A; Bröcker EB
    Hautarzt; 1998 Jan; 49(1):17-22. PubMed ID: 9522188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Brain metastases of malignant melanomas].
    Boaziz C; Breau JL; Morere JF; Israël L
    Bull Cancer; 1991; 78(4):347-53. PubMed ID: 1859902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain metastases as the presenting manifestation of malignant melanoma. A case report.
    Hulick PR
    Del Med J; 1995 Apr; 67(4):231-4. PubMed ID: 7768311
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2.
    Becker JC; Terheyden P; Kämpgen E; Wagner S; Neumann C; Schadendorf D; Steinmann A; Wittenberg G; Lieb W; Bröcker EB
    Br J Cancer; 2002 Oct; 87(8):840-5. PubMed ID: 12373596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ipilimumab with fotemustine in metastatic melanoma.
    Garbe C
    Lancet Oncol; 2012 Sep; 13(9):851-2. PubMed ID: 22894885
    [No Abstract]   [Full Text] [Related]  

  • 39. Persistent thrombocytopenia during melanoma treatment with fotemustine.
    Turrisi G; Sozzi P; Marinozzi C; Clerico MA
    Melanoma Res; 2006 Dec; 16(6):543-4. PubMed ID: 17119456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
    Leccia MT; Planchamp F; Sassolas B; Combemale P; Modiano P; Bedane C; Cupissol D; Derrey S; Dygai-Cochet I; Lamant L; Lubrano V; Mirabel X; Mourrégot A; Rougé Bugat ME; Siegrist S; Thariat J; Tiffet O; Truc G; Verdoni L; Mazeau-Woynar V
    Ann Dermatol Venereol; 2014 Feb; 141(2):111-21. PubMed ID: 24507205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.